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Abstract:  
1-Deoxysphingolipds (1-deoxySLs) are atypical neurotoxic sphingolipids which are formed by 
the serine-palmitoyltransferase (SPT). Pathologically elevated 1-deoxySL level cause hereditary 
sensory and autonomic neuropathy type 1 (HSAN1) an axonal neuropathy which is associated 
with several missense mutations in SPT. Oral L-serine supplementation suppressed 1-deoxySLs 
formation in HSAN1patients and preserved the nerve function in an HSAN1 mouse model. As 1-
deoxySLs are also elevated in patients with type 2 diabetes mellitus, L-serine supplementation 
could also be a therapeutic option for diabetic neuropathy (DN). This was tested in diabetic STZ 
rats in a preventive and therapeutic treatment scheme. Diabetic rats showed significantly 
increased plasma 1-deoxySL levels and L-serine supplementation lowered 1-deoxySLs levels in 
both treatment schemes (p<0.0001). L-serine had no significant effect on hyperglycemia, body 
weight and food intake. Mechanical sensitivity was significantly improved in the preventive (p < 
0.01) and therapeutic scheme (p < 0.001). NCV significantly improved in the preventive group 
only (p < 0.05).  Overall NCV showed a highly significant (p = 5.2E-12) inverse correlation with 
plasma 1-deoxySL levels. In summary our data support the hypothesis that 1-deoxySLs are 
involved in the pathology of DN and that an oral L-serine supplementation could be a novel 
therapeutic option for treating DN.  
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Introduction 
Diabetic neuropathy (DN) is one of the most important causes of morbidity and premature 
mortality in patients with diabetes (1; 2). It generates a great economic burden through its 
complications, including foot ulcers due to sensory loss and premature death due to dysregulated 
autonomic functions (3; 4). DN is a length-dependent axonal sensorimotor and autonomic 
neuropathy and usually starts in the lower extremities with either negative (e.g. numbness) or 
positive symptoms (e.g. neuropathic pain). Symptoms are mainly sensory and symmetrical on 
both sides with a “stocking and gloves” distribution. Yet, no adequate treatment for DN is 
available. Therapeutic options are restricted to symptomatic pain treatment with costly 
medications and potential side effects.  
The underlying pathomechanisms leading to DN are not yet understood. Several histo-
pathological changes are associated with DN including micro-angiopathy (5; 6), direct nerve 
injury and injury of the nerve supporting cells (e.g. Schwan cells in the PNS or satellite cells in 
the DRGs). Hyperglycemia is considered as an important contributor in the pathogenesis of DN 
(7-10) but even a tight control of hyperglycemia is not sufficient to prevent DN (3; 11-13). This 
suggests that other factors, apart from hyperglycemia, are underlying the pathogenesis of DN. 
Sphingolipids have been identified over the last years as emerging players in insulin resistance 
and T2DM (14). Sphingolipids are a heterogeneous class of lipids and essential components of 
the plasma membrane and plasma lipoproteins. The initial and rate-determining step in de novo 
synthesis of sphingolipids is the condensation of palmitoyl-CoA and the amino acid L-serine– a 
reaction which is catalyzed by the enzyme Serine-Palmitoyltransferase (SPT) (15). Several 
missense mutations in SPT cause the hereditary sensory and autonomic neuropathy type 1 
(HSAN1), a rare length-dependent axonal neuropathy characterized by sensory loss, ulcers, and 
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autonomic dysfunction (16; 17). HSAN-1-causing mutations in SPT induce a gain of function by 
shifting the substrate affinity of the enzyme from L-serine to the non-canonical substrates L-
alanine and glycine (18). This forms an atypical class of 1-deoxysphingolipids (1-deoxySL) 
which lack the C1-hydroxyl group of the canonical sphingolipids. Consequently, 1-deoxySLs 
cannot be metabolized to complex sphingolipids nor degraded by the canonical pathway which 
requires the formation of sphingosine-1-phosphate as a catabolic intermediate. 1-deoxySL levels 
are significantly elevated in the plasma of HSAN1 patients as well as in plasma and nerves of a 
transgenic HSAN1 mouse model (18; 19). They are neurotoxic by inducing branching defects 
and neurite retraction in cultured primary DRG neurons (18). Interestingly, wild-type SPT is also 
able to metabolize L-alanine under certain metabolic conditions (20). We demonstrated in 
several clinical studies that 1-deoxySLs are significantly elevated in the plasma of individuals 
with MetS and T2DM (21; 22). Although the etiologies of HSAN1 and DN are different, the 
clinical presentation is rather similar. Both conditions are characterized by a painful, progressive 
and length-dependent late onset axonopathy which typically affects distal extremities first. The 
degeneration of small intra-epidermal sensory fibers results in the loss of pain sensation, which 
in turn leads to painless injuries and neuropathic pain attacks. Both, HSAN1 and DN are 
associated with painless skin ulcers and severely impaired wound healing which is not typically 
seen in other peripheral neuropathies. We previously showed that oral L-serine supplementation 
significantly reduces 1-deoxySLs level in the HSAN1 mouse models and patients (19). 
Moreover, L-serine-supplemented HSAN1 mice were protected from the development of 
neuropathy.  On the basis of these findings, we were interested whether L-serine is also effective 
in lowering plasma 1-deoxySLs in context of diabetes and whether such a treatment could be a 
therapeutic option for DN. 
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Results  
Serine-enriched diet increases plasma serine but does not affect body weight, hyperglycemia, 
hypertriglyceridemia or food intake in STZ rats. 
A streptozotocin (STZ) induced diabetic rat model was used to test the effect of an oral L-serine 
supplementation on 1-deoxySL formation and DN. Two experimental designs were employed 
(Fig.1).  In the preventive schedule, the animals had immediate access to either a serine-enriched 
or a standard diet. In the therapeutic schedule, animals remained on a standard diet for 8 weeks 
after STZ injection and were then randomized into groups receiving either a serine-enriched or a 
standard diet. STZ-treated animals developed hyperglycemia (Fig. 2A-C) within 48 hours post-
injection. Hyperglycemia (400- 800 mg/dl or 22.2- 44.4 mmol/l) persisted in the STZ groups 
until the end of the study (preventive 18 weeks; therapeutic 24 weeks). Plasma triglycerides (TG) 
increased significantly in the diabetic animals reaching a maximum after 4 weeks (300-400 
mg/dl or 3.38- 4.52 mmol/l) and remained elevated until the end of the study (Fig. 2D-F). Plasma 
serine levels were 4- 6 fold higher in the serine-supplemented animals (Fig 2G-I). This effect 
persisted until the end of the study. Serine supplementation did not affect hyperglycemia or 
hypertriglyceridemia (Fig2A-F) and had no influence on body weight, food or water 
consumption (Supplementary figure 1 A-I). In contrast to controls the STZ group failed to gain 
body weight despite the increased food and water intake (Supplementary figure 1 A-C).  
Serine enriched diet lowers 1-deoxysphingolipids in the plasma of STZ rats without affecting 
other sphingolipids 
Sphingoid bases in plasma are usually conjugated to a variety of N-linked fatty acids and 
different head groups. As we were primarily interested in the sphingoid base profile, the N-acyls 
and head groups were removed by acid hydrolysis. The profile of the free sphingoid bases was 
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analysed by LC-MS. Consequently, the herein reported sphingoid base concentrations reflect the 
total concentrations of sphingolipids which are formed on a specific sphingoid base backbone. 
Sphingolipids containing a C18SO backbone were the dominant forms in plasma and did not 
differ between the groups (Fig. 3 A-C). C18SA levels were minor but increased initially in the 
serine-supplemented STZ animals, reaching a maximum after 3-4 weeks and then decreased 
again but remained slightly elevated until the end of the study (Fig.3 D-F). C18-SAdiene and 
C18PhytoSO (Fig. 3 G-L) were significantly elevated in all diabetic groups but did not change 
upon serine supplementation. 
Plasma 1-deoxySA was significantly elevated in the STZ rats on standard diet but remained low 
in the serine supplemented STZ rats. In the preventive schedule, the plasma 1-deoxySA was 
significantly higher in the STZ animals on standard diet (p < 0.0001) compared to the other 
groups (Fig. 4A-C). 1-deoxySA increased from 0.03 µmol/l ± 0.003 at the beginning of the study 
to reach 0.05 µmol/l ± 0.007 before sacrifice in the STZ rats on standard diet (Fig 3A, C) 
whereas the levels remained low in the serine-fed STZ rats until the end of the preventive 
scheme (0.016 µmol/l ± 0.001 at week 17 post-STZ injection).  
For the therapeutic scheme, we observed a rapid decrease of 1-deoxySA to control levels after 
switching to the serine-enriched diet in week 8 whereas 1-deoxySA levels remained high in the 
diabetic rats on standard diet (Fig. 4B). This effect remained significant until the end of the study 
(Fig. 4B). No significant difference in 1-deoxySA levels was observed between the control rats 
with and without serine supplementation.  
Plasma levels of C16SO (supplementary figure 2 A-C) did not differ significantly between the 
groups at baseline but were significantly reduced in the STZ groups in both scheme at the end of 
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the study. Plasma levels of C17SO, C20SO and C20SA were not significantly different between 
groups and did not change upon treatment (Supplementary figure 2 D-L).  
Interestingly, we could not detect significant 1-deoxySA levels directly in nervous tissues 
including sciatic nerve, spinal cord, dorsal root ganglia, of neither control nor of diabetic animals 
(Supplementary figure 3). Overall sphingoid bases distribution in the nervous tissues were 
similar between STZ and control animal. In comparison to plasma, nervous tissue had higher 
proportion of C18SA and C17SO and lower proportion of C18SAdiene.   
Serine-enriched diet improves the diabetic neuropathy phenotype in STZ rats 
STZ rats on standard diet showed a significant decrease in the force withdrawal threshold which 
was significantly improved in both L-serine supplemented groups (Fig 5A-C). In the preventive 
scheme, the force withdrawal threshold remained stable for the serine treated STZ animals 
(103.2 g ±11.6 at week 14) while the STZ rats on standard diet showed a continuous decrease 
over the whole study period ( 54.6 g ± 5.0 at week 14). A significantly improved mechanical 
sensitivity was observed for the serine-treated STZ rats versus those on standard diet at the end 
of the preventive protocol (p < 0.01). No difference was seen between the control groups. Similar 
results were obtained in the therapeutic scheme. Mechanical sensitivity was not significantly 
different between the STZ groups at the start of the serine supplementation on week 8 (74.5 g ± 
6.6 in the STZ group on a standard diet and 73.4 g ± 8.4 in the STZ group on a serine-enriched 
diet). However, L-serine supplementation improved mechanical sensitivity and the differences 
became significant at week 23 prior to sacrifice (52.0 g ± 5.4 on standard diet and 101.8g ± 13.0 
on serine-enriched diet, p < 0.001) (Fig. 5C). 
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Thermal response latency (Fig. 5D-E) was not significantly different between control and STZ 
animals in the preventive group but reached significance in the therapeutic group (Fig .5F).  L-
serine supplementation showed no significant effect on thermal response latency. 
Nerve conduction velocity (NCV) decreased significantly in the STZ groups on the standard diet 
(Fig. 6 A) ( p < 0.0001 comparing the STZ treated rats on standard vs control diet in the 
preventive schedule;  p < 0.001  comparing the same groups in the therapeutic schedule). In the 
preventive scheme NCV was significantly improved in the L-serine supplemented STZ rats (30.3 
m/sec ± 2.2 in the STZ rats on the serine-enriched diet vs.23.8 m/sec ± 1.0 for the STZ rats on 
the standard diet, p < 0.05). By trend NCV also improved in the therapeutic scheme but did not 
reach the statistical significance until the end of the study (Fig. 6A). NA+ /K+ ATPase activity 
was significantly decreased in STZ rats on standard diet in both the preventive and therapeutic 
groups (Fig 6B) (p < 0.001 and p < 0.01, respectively). For both treatment schemes there was a 
trend for improved NA+ /K+ ATPase activity upon serine supplementation but did not reach 
statistical significance after correcting for multiple comparisons. Intra-epidermal nerve fiber 
density was not different between control and diabetic rats (Fig 6C).  
For all groups we observed a highly significant inverse correlation between plasma 1-deoxySA 
levels and NCV (r = 0.62, p = 5.23 *10-12) (Fig. 6D).  
Morphological and Morphometric analysis of sciatic nerve and DRGNerve morphometry (Fig. 
7A-D) indicated a change in the distribution of axon and nerve fiber diameters with less 
percentage of large diameter fibers. This was partly restored upon L-serine supplementation in 
the preventive but not in the therapeutic group. In the preventive group the distribution of axon 
and nerve fiber diameters was significantly different in the L-serine supplemented diabetic 
animal compared to those on standard diet (p = 0.0001 for the  distribution of axon diameter and 
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p  < 0.0001 for the  distribution of nerve fiber diameter ). This is mainly a result of the increase 
in percentage of axons with larger diameter >7µm and a decrease in those will smaller diameter 
(3-7 µm). No significant difference in the distributions of axon/fiber diameter was seen upon 
serine supplementation for the therapeutic group. DRG neurons were smaller in size in the 
diabetic rats compared to controls and did not change upon supplementation (Fig.8 A). The 
morphometric analysis showed a significantly reduced somatic, nuclear and nucleolar size in the 
DRG neurons of the diabetic animals compared to controls independent of the diet (Fig.8 C-D). 
No evidence of cell damage was observed and satellite cells were normal in all groups 
 
Discussion  
We demonstrated previously that oral L-serine supplementation is effectively lowering 1-
deoxySL plasma levels in HSAN1 animal model and patients (19). Here, we report that L-serine 
supplementation is also effective in reducing plasma 1-deoxySL levels in a diabetic STZ rat 
model.  The reduced 1-dexoySL plasma levels were associated with improved sensory nerve 
function in the supplemented animals but had no effect on hyperglycemia or plasma TG levels 
(Fig.2 A-F). We found significant improvements in several neuropathy parameters including 
mechanical sensitivity, NCV, the percentage of large diameter fibers/axons and by trend an 
improved neuronal NA+ /K+ ATPase activity. This indicates that lowering plasma 1-deoxySL 
levels is beneficial and protects from diabetes associated nerve damage. The negative influence 
of elevated plasma 1-deoxySL levels on nerve function is also supported by a highly significant 
negative overall correlation between plasma 1-deoxySLs and NCV.   
STZ rats are generally considered to be a T1DM model which is, however, not fully correct as 
hyperglycemia in these animals is typically also early associated with dyslipidemia and elevated 
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plasma TGs (Fig.2 D-F). In T1DM patient DN often develops after a period of sustained or 
uncontrolled hyperglycemia (23) which coincides with dyslipidemia in these patients (24). In 
T2DM patients, dyslipidemia appears early and even precedes the onset of hyperglycemia. 
Hypertriglyceridemia has been shown to correlate with the progression of diabetic neuropathy 
independently of glycemic control (25; 26).  In the European Diabetes Prospective 
Complications Study (EURODIAB), hypertriglyceridemia was identified as an independent 
predictor for the development of diabetic neuropathy in T1DM even after adjusting for the 
duration of diabetes and HbA1c (27). Plasma TG and 1-deoxySLs levels were shown to be 
independent variables but show a strong and highly significant correlation (21; 22). This 
correlation cannot be easily explained by direct metabolic interactions since 1-deoxySLs are 
formed by SPT due to a shift of the amino acid and not of the lipid substrate.  In contrast to TGs 
whose plasma levels are in the millimolar range, 1-deoxySLs are present in plasma and 
neurotoxic in vitro in the low micromolar range.  
The mechanisms through which 1-deoxySLs exert their neurotoxic effects are not yet 
understood. They impair length, number and branching of neurites in cultured dorsal root ganglia 
(DRGs) (28) and inhibit neurite growth and induced cytotoxicity in primary dopaminergic 
neurons (29). It was reported that 1-deoxySA can bind and activate endothelial differentiation 
gene (EDG) receptors in cell culture (30; 31). The EDG receptor family consists of several G 
protein coupled receptors that regulate various neuronal functions (32). Alternatively, 1-
deoxySA may modulate protein kinase C (PKC) activity as it was shown previously for other 
free sphingoid bases (33-35). PKC is known to be involved in the pathogenesis of diabetic 
microvascular complications including diabetic neuropathy (36). Another line of evidence 
suggests that 1-deoxySLs impair neuronal cytoskeleton dynamics and growth cone formation 
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(18). It was shown that 1-deoxySA promotes the disassembly of actin stress fibers in Vero cells 
(37) and alters cytoskeleton dynamics in cultured  INS-1 beta cells, resulting in the intracellular 
accumulation of filamentous actin, impaired insulin secretion and the activation of Rac1 (38). 
However, we cannot fully exclude that the observed beneficial effects of L-serine are also 
mediated by other, not yet defined, neurotropic mechanisms. Earlier reports showed that the 
addition of L-serine to embryonic chicken DRGs improves neuronal differentiation and survival 
in-vitro (39). Neurons cannot synthesize L-serine and therefore depend on the supply of serine 
from surrounding cells like glia and satellite cells.  Further mechanistic studies are, therefore, 
necessary to dissect the interplay between 1-deoxySLs formation and the protective effect of 
serine in the context of DN.  However, independent of the underlying mechanisms, our studies 
unraveled oral L-serine supplementation as a candidate treatment for diabetic neuropathy that 
merits further validation in clinical trials of patients with diabetes mellitus.  
 
Materials and Methods 
Animal experiments: 
The Statement of Compliance (Assurance) with Standards for Humane Care and Use of 
Laboratory Animals has been reviewed (10/28/2008) and approved by the National Institutes of 
Health-Office for Protection from Research Risks (5023-01, expiration 10/31/2013). Male 
Sprague-Dawley rats (180-200 g, Charles River, Calco, Italy) were used for the study. The 
animals had access to food and water ad libitum. Diabetes was induced in overnight-fasted rats 
by a single intra-peritoneal injection of 60 mg/kg streptozotocin (STZ) (Sigma, St. Louis, MO) 
dissolved in sodium citrate buffer (pH 4.5). Control rats were injected with sodium citrate buffer 
(pH 4.5) only. Hyperglycemia was confirmed by measuring glycosuria 48 h after STZ injection 
(Keto-Diabur test, Roche Diagnostics, Spa, Italy). Blood glucose was determined after tail 
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bleeding using the Ascensia Elite assay (Bayer, Basel, Switzerland). Food and water intake were 
assessed at the specified time points by averaging over 2-days period. At the end of the study, 
animals were sacrificed; tissues were dissected and immediately frozen in liquid N2. 
Serine supplementation: 
The animals had access to either a serine-enriched (containing 10% L- serine for the control 
group and 5% serine for the STZ group) or a standard diet (4RF21, Mucedola s.r.l, Milan, Italy). 
The serine content in the food for the STZ animals was half to compensate for doubled food 
intake of the STZ animals. 
Behavioural tests and electrophysiology: 
Thermal and mechanical nociception were assessed as behavioral measures for the diabetic 
neuropathy. The nociceptive threshold to radiant heat was quantified using the hot-plate paw 
withdrawal test (40). In brief, a 40-cm-high Plexiglas cylinder was suspended over the hot plate, 
and the temperature was maintained at 50°C to give a latency period of approximately 10 s for 
control rats. Withdrawal latency was defined as the time between placing the rat on the hot plate 
and the time of withdrawal and licking the hind paw (or manifesting discomfort). Mechanical 
allodynia on the plantar surface of the rat was assessed by a dynamic paw withdrawal test with a 
Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy), which generates a linearly 
increasing mechanical force. The paw withdrawal reflex was recorded automatically by 
measuring the latency until withdrawal in response to the applied force.  
Nerve Conduction Velocity (NCV): 
NCV was measured as described previously (40). In brief, the anti-dromic sensory NCV in the 
tail nerve was assessed by placing recording ring electrodes distally in the tail. Stimulating ring 
electrodes were placed 5 and 10 cm proximally from the recording point. The latencies of the 
potentials, recorded at the two sites after nerve stimulation, were determined (peak to peak), and 
Page 12 of 30Diabetes
13 
 
NCV was calculated. All of the neurophysiological determinations were performed under 
standard conditions and at a controlled temperature (room and animals). Core temperature was 
maintained at 37°C by using heating pads and lamps. 
Morphometric Analysis of Caudal Nerve  
The caudal nerve was fixed in 3% glutaraldehyde, post-fixed in OsO4, epoxy resin embedded 
and used for light microscopy and for morphometric analysis. Semi-thin sections (1 µm) were 
prepared, stained with toluidine blue and examined with a Nikon Coolscope light microscope 
(Nikon Instruments, Calenzano, Italy). For the morphometric analysis sections were analyzed in 
a photomicroscope (Nikon Eclipse E200; Leica Microsystems GmbH, Wetzlar, Germany) at a 
magnification of 60× and the morphometric analysis was performed using a QWin automatic 
image analyzer (Leica Microsystems GmbH, Wetzlar, Germany).  All myelinated fibers in 
randomly selected sections from all specimens were counted and the external (total) and internal 
(axonal) diameters of myelinated fibers were measured (at least 500 myelinated fibers/nerves). 
From both axonal and total fiber diameters, the histogram of fiber distribution was calculated and 
the ratio between the two diameters (g-ratio) automatically calculated for each set of individual 
axon and fiber diameter. Histograms of the population distribution of myelinated fibers and 
axons, separated into class intervals increasing by 1.0 µm, were constructed. 
Morphometric Analysis of DRG  
At the end of the treatment period three L4-L5 dorsal root ganglia (DRG)/animals were collected 
and post-fixed in OsO4, epoxy resin embedded and used for light microscopy. For each animal, 
several semi-thin sections (1 µm) were prepared from randomly selected blocks and were stained 
with toluidine blue then examined with a Nikon Coolscope light microscope (Nikon Instruments, 
Calenzano, Italy). The semi-thin sections were analyzed with a computer-assisted image analyzer 
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(Image J NIH software). The somatic, nuclear and nucleolar sizes of DRG sensory neurons were 
measured for at least 200 DRG neurons/animal in randomly selected sections. 
All the morphometric measurements on caudal nerve and DRG were performed by the same 
examiner who was blinded regarding the belonging of the specimen to any experimental group. 
Intra-epidermal nerve fiber density 
Small fibers peripheral nerve damage was assessed by the quantification of the IENF density in 
the skin of the hind paw footpad (40).  Hind paws were collected at sacrifice and 3-mm round-
shaped biopsies, which included epidermis and dermis, were taken from the plantar glabrous skin 
and immediately fixed by immersion in 2% paraformaldehyde-lysine-periodate for 24 h at 4 °C, 
then cryoprotected overnight and serially cut with a cryostat to obtain 20 µm sections. Three 
sections from each sample were randomly selected and immunostained with rabbit polyclonal 
anti-protein gene product 9.5 antibodies (PGP 9.5; AbD Serotec, Kidlington, Oxfordshire, UK) 
using a free-floating protocol. One observer blinded to the status of the rats, independently 
counted the total number of PGP 9.5-positive IENFs in each section under a light microscope at 
high magnification. Individual fibers were counted as they crossed the dermal–epidermal 
junction or being located in epidermal layer. Secondary branching within the epidermis was 
excluded. The length of the epidermis was measured using a computerized system (Image-Pro 
Plus, Media Cybernetics, Inc., Silver Spring, MD, US), and the linear density of IENF was 
obtained. 
NA
+
/K
+
ATPase activity: 
Tibial stumps collected at sacrifice were dissected, desheathed and homogenized in chilled 
solution containing 0.25 M sucrose, 1.25 mM EGTA and 10 mM Tris, pH 7.5, at 1:20 (w/v), 
homogenized in a glass-glass Elvehjem-Potter (DISA, Italy) and stored at –80°C for ATPase 
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determinations. Na+/K+-ATPase activity was determined spectrophotometrically as described 
previously (40). Protein content in homogenates was determined according to Lowry’s with 
bovine serum albumin as standard. 
Sphingolipid analysis:  
The sphingoid base composition of the extracted lipids was analysed after hydrolysis as 
described before (22). Isotope labelled d7-sphingosine and d7-sphinganine (d7SA, d7SO; 
200pmol; Avanti Polar Lipids, Alabaster, Alabama, US) was used as an internal standard. The 
sphingoid bases were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, Interchim, 
Montluçon, France) and analysed on a TSQ Quantum Ultra mass spec (Thermo, Reinach, BL, 
Switzerland). Each sample was measured as a singleton. Intra- and Inter-assay coefficient of 
variation (CV %) of the method was between 5% and 20%. The plasma and tissue levels of 
C16SO, C17SO, C18SO, C18SA, C18SAdiene, C18PhytoSO, C20SO, C20SA, and 1-deoxySA 
sphingoid bases were quantified. 
Amino Acid analysis: 
Amino acids were analysed on a Zorbax Eclypse AAA column (150 x 4.5mm, 5µM, Agilent) 
according to manufacturer’s instructions. A Shimadzu LC2010 HPLC system connected to a 
fluorescence detector (Hewlet Packard) was used for detection. 
Triglyceride measurement:  
Triglycerides were measured using an enzymatic assay Kit (Sigma-Aldrich, St. Louis, MO, US) 
according to the manufacture`s protocol.  
Statistical analysis: 
Data are shown as mean ± SEM. For normally distributed variables, one way ANOVA is 
performed followed by the Bonferroni correction for the multiple comparisons. In the Bonferroni 
Page 15 of 30 Diabetes
16 
 
correction, only four comparisons were considered, control on standard diet vs. control on serine 
diet; control on standard diet vs. streptozotocin on standard diet, control on serine diet vs. 
streptozotocin on serine diet and streptozotocin on standard diet vs. streptozotocin on serine diet. 
Variables which were not normally distributed were log-transformed. The statistical analysis was 
performed using SPSS 16.0 (IBM, Zurich, Switzerland) and GraphPad Prism 5.04 (GraphPad 
Software, Inc., San Diego, CA). 
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FigureS1. Effect of serine on body weight, food and water intake. Line plots showing the 
body weight (A-B), blood glucose (C-D), food (E-F) and water intake (G-H) of the animal 
used in the study. The plots show the values over the entire period of the preventive (Left) and 
therapeutic (middle) schedules. Scatter plots show the values of the body weight (C), food (F) 
and water intake (I) at week 16 post-STZ injection for the preventive group and week 24 post-
STZ injection for the therapeutic group. The values are expressed as mean ± SEM.  p values 
are calculated using ANOVA followed by the Bonferroni correction. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001 . CTRL Std, control on standard diet; CTRL Ser, control on 
serine diet; STZ  Std, STZ on standard diet; STZ Ser ,STZ on serine diet. 
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Figure S2. Effect of serine-enriched diet on plasma levels of atypical sphingolipids with 
different chain lengths. Line plots show plasma levels of C16SO (A-B), C17SO (D-D), C20SO 
(G-H), C20SA-based sphingolipids (J-K) for the preventive (Left) and therapeutic (middle) 
schedules over the study duration. Scatter plots show the values for C16SO (C), C17SO (F), 
C20SO (I), C20SA (L) at week 17 post-STZ for the preventive group and week 24 post STZ for 
the therapeutic groups. The values are expressed as mean ± SEM.  p values are calculated 
using ANOVA followed by the Bonferroni correction. * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001CTRL Std, control on standard diet; CTRL Ser, control on serine diet; STZ 
Std, STZ on standard diet; STZ Ser, STZ on serine diet 
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Figure S3. Sphingolipid distribution by backbone in the plasma, sciatic nerve, dorsal 
root ganglia (DRGs) and spinal cord. The total sphingolipid content is set to 100% and the 
relative ratio of each sphingoid base backbone is shown.  CTRL, control animals; STZ, 
streptozotocin animals; Std standard diet; Ser, serine diet; Prev, preventive scheme; Ther, 
therapeutic scheme.  
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